Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

CRXA and partner GlaxoSmithKline plc (GSK; LSE:GSK, London, U.K.) received a complete review letter from the FDA requesting additional clinical and manufacturing information for Bexxar to treat

Read the full 276 word article

How to gain access

Continue reading with a
two-week free trial.